Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement.
RemeGen Co., Ltd. has announced a discloseable transaction involving the purchase of a principal-guaranteed wealth management product worth RMB400 million from SPDB Yantai Branch. This transaction, along with a prior agreement made in October 2025, is part of the company’s strategy to utilize idle self-owned funds for cash management, reflecting a cautious approach to financial management amidst market fluctuations. The purchase is subject to reporting and announcement requirements under the Hong Kong Listing Rules due to the aggregated transaction value exceeding 5% of the applicable percentage ratios.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$86.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the biotechnology and pharmaceutical industry. The company is engaged in the development and commercialization of innovative drugs and therapies, with a market focus on addressing unmet medical needs.
Average Trading Volume: 7,487,123
Technical Sentiment Signal: Buy
Current Market Cap: HK$56.77B
Learn more about 9995 stock on TipRanks’ Stock Analysis page.